Effects of 5-Aza-2′-deoxycytidine on the methylation state and function of the WWOX gene in the HO-8910 ovarian cancer cell line

Yan, Hongchao; Yu, Nan; Jianye, Tong

doi:10.3892/ol.2013.1438

Cited by 13 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, WWOX-negative cases exhibited restored WWOX expression following treatment, and the mean expression level in the WWOX-positive patients was relatively elevated after receiving clinical therapy, indicating that WWOX has the potential to be a candidate predictive marker for treatment. Supporting evidence from another study similarly showed that WWOX protein expression was significantly elevated in the 5-Aza-CdR-treated ovarian cancer group (28). Recently published data indicated that in the treated breast cancer cases with a tumor expressing moderate or strong WWOX protein, recurrence-free survival was improved (29).…”

Section: A B Csupporting

confidence: 64%

Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies

et al. 2016

View full text Add to dashboard Cite

Abstract. The role of the WW domain-containing oxidoreductase (WWOX) gene in multiple types of solid human cancers has been documented extensively thus far. Recently, we investigated the in vitro effects of WWOX overexpression and observed marked growth arrest in human leukemia cells; however, the clinical characterization of WWOX in leukemia remains poorly investigated. The present study evaluated the WWOX expression profiles of 182 patients with leukemia of different types and 5 leukemic cell lines, using reverse transcription-polymerase chain reaction and immunofluorescence analysis. The results found that WWOX mRNA and WWOX protein expression was significantly reduced or absent in the leukemia cases and cell lines compared with paired controls. The WWOX-positive rate was also lower in the leukemia cases compared with the rate of the normal controls. Notably, the WWOX level was reduced in newly diagnosed and relapsed cases, or in chronic myelogenous leukemia in the blastic phase, yet elevated in remission samples. Moreover, WWOX-negative cases exhibited WWOX expression restoration following induced remission. These findings suggest that WWOX may contribute to the occurrence and development of leukemia, and that it has potential to be a good biomarker or predictor for leukemia therapy.

show abstract

Section: A B Csupporting

confidence: 64%

Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies

et al. 2016

View full text Add to dashboard Cite

show abstract

“…18 The methyltransferase-specific inhibitor 5-aza-CdR is a pyrimidine analogue whose mechanism is to combine with DNA during DNA replication, form covalent complexes with DNMT1, inhibit the enzyme's methyl transfer activity, produce low-methyl annihilator chains, and reduce the hypermethylation of the gene promoter region to recover gene activity. 19 The study first showed that abnormal methylation of the P16 gene promoter by hyperoxia contributed to the increase of the proliferation of LFs. We then used this hyperoxia-induced BPD mouse model to investigate the activity of 5-aza-CdR in inhibiting the growth and proliferation of LFs.…”

Section: -Aza-cdr Inhibits Fibroblasts Proliferationmentioning

confidence: 99%

5-aza-2′-deoxycytidine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats Exposed to Hyperoxia

Cao

et al. 2017

Pediatrics & Neonatology

View full text Add to dashboard Cite

show abstract

“…DZNep and 5‐Aza‐CdR can antagonize tumor cell proliferation, migration, and invasion (Natsume et al, ; Yan et al, ). Our current results in breast cancer cells further validate these findings.…”

Section: Discussionmentioning

confidence: 99%

Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells

Pan¹,

Guo²,

Maimaiti³

et al. 2016

Cell Biology International

View full text Add to dashboard Cite

EZH2, the catalytic subunit of polycomb repressor complex 2, has oncogenic properties, whereas RASSF2A, a Ras association domain family protein, has a tumor suppressor role in many types of human cancer. However, the interrelationship between these two genes remains unclear. Here, we showed that the downregulation of EZH2 reduces CpG island methylation of the RASSF2A promoter, thereby leading to increased RASSF2A expression. Our findings also showed that knockdown of EZH2 increased RASSF2A expression in the human breast cancer cell line MCF-7 in cooperation with DNMT1. This was similar to the effect of 5-Aza-CdR, a DNA methylation inhibitor that reactivates tumor suppressor genes and activated RASSF2A expression in our study. The EZH2 inhibitor DZNep markedly suppressed the proliferation, migration, and invasion of MCF-7 cells treated with ADR and TAM. EZH2 inhibits the expression of tumor suppressor gene RASSF2A via promoter hypermethylation. Thus, it plays an important role in tumorigenesis and is a potential therapeutic target for the treatment of breast cancer.

show abstract

Effects of 5-Aza-2′-deoxycytidine on the methylation state and function of the WWOX gene in the HO-8910 ovarian cancer cell line

Cited by 13 publications

References 14 publications

Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies

Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies

5-aza-2′-deoxycytidine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats Exposed to Hyperoxia

Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells

Contact Info

Product

Resources

About